EUVIMEDEUVIMED entdecken
Open Access

Use of Recommended Neurodiagnostic Evaluation Among Patients With Drug-Resistant Epilepsy

Matthew Spotnitz, Cameron D Ekanayake, Anna Ostropolets, Guy M McKhann, Hyunmi Choi, Ruth Ottman, Alfred I Neugut, George Hripcsak, Karthik Natarajan, Brett E Youngerman

JAMA Neurology · 2024

DOI: 10.1001/jamaneurol.2024.0551 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Neurology, 2024. Verfasst von Matthew Spotnitz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York. Hauptthemen laut MEDLINE: Drug Resistant Epilepsy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Interdisciplinary practice parameters recommend that patients with drug-resistant epilepsy (DRE) undergo comprehensive neurodiagnostic evaluation, including presurgical assessment. Reporting from specialized centers suggests long delays to referral and underuse of surgery; however, longitudinal data are limited to characterize neurodiagnostic evaluation among patients with DRE in more diverse US settings and populations.

Objective

To examine the rate and factors associated with neurodiagnostic studies and comprehensive evaluation among patients with DRE within 3 US cohorts. Design, Setting, and Participants A retrospective cross-sectional study was conducted using the Observational Medical Outcomes Partnership Common Data Model including US multistate Medicaid data, commercial claims data, and Columbia University Medical Center (CUMC) electronic health record data. Patients meeting a validated computable phenotype algorithm for DRE between January 1, 2015, and April 1, 2020, were included. No eligible participants were excluded. Exposure Demographic and clinical variables were queried. Main Outcomes and Measures The proportion of patients receiving a composite proxy for comprehensive neurodiagnostic evaluation, including (1) magnetic resonance or other advanced brain imaging, (2) video electroencephalography, and (3) neuropsychological evaluation within 2 years of meeting the inclusion criteria.

Results

A total of 33 542 patients with DRE were included in the Medicaid cohort, 22 496 in the commercial insurance cohort, and 2741 in the CUMC database. A total of 31 516 patients (53.6%) were women. The proportion of patients meeting the comprehensive evaluation main outcome in the Medicaid cohort was 4.5% (n = 1520); in the commercial insurance cohort, 8.0% (n = 1796); and in the CUMC cohort, 14.3% (n = 393). Video electroencephalography (24.9% Medicaid, 28.4% commercial, 63.2% CUMC) and magnetic resonance imaging of the brain (35.6% Medicaid, 43.4% commercial, 52.6% CUMC) were performed more regularly than neuropsychological evaluation (13.0% Medicaid, 16.6% commercial, 19.2% CUMC) or advanced imaging (3.2% Medicaid, 5.4% commercial, 13.1% CUMC). Factors independently associated with greater odds of evaluation across all 3 data sets included the number of inpatient and outpatient nonemergency epilepsy visits and focal rather than generalized epilepsy. Conclusions and Relevance The findings of this study suggest there is a gap in the use of diagnostic studies to evaluate patients with DRE. Care setting, insurance type, frequency of nonemergency visits, and epilepsy type are all associated with evaluation. A common data model can be used to measure adherence with best practices across a variety of observational data sources.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistant EpilepsyHumansFemaleMaleAdultCross-Sectional StudiesRetrospective StudiesMiddle AgedYoung AdultUnited StatesElectroencephalographyAdolescentMagnetic Resonance ImagingNeuroimagingMedicaid

Autor:innen und Institutionen

  • Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.
  • Department of Neurological Surgery, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.
  • Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.
  • The Gertrude H. Sergievsky Center, Columbia University Irving Medical Center, New York, New York.
  • Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
  • Division of Translational Epidemiology and Mental Health Equity, New York State Psychiatric Institute, New York.

Förderung

  • NIA NIH HHS

Zitieren

APA

Spotnitz, M., Ekanayake, C. D., Ostropolets, A., McKhann, G. M., Choi, H., Ottman, R., Neugut, A. I., Hripcsak, G., Natarajan, K., & Youngerman, B. E. (2024). Use of Recommended Neurodiagnostic Evaluation Among Patients With Drug-Resistant Epilepsy. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2024.0551

Vancouver

Spotnitz M, Ekanayake CD, Ostropolets A, McKhann GM, Choi H, Ottman R, et al. Use of Recommended Neurodiagnostic Evaluation Among Patients With Drug-Resistant Epilepsy. JAMA Neurology. 2024. doi:10.1001/jamaneurol.2024.0551

BibTeX
@article{Spotnitz2024,
  author = {Spotnitz, Matthew and Ekanayake, Cameron D and Ostropolets, Anna and McKhann, Guy M and Choi, Hyunmi and Ottman, Ruth and Neugut, Alfred I and Hripcsak, George and Natarajan, Karthik and Youngerman, Brett E},
  title = {Use of Recommended Neurodiagnostic Evaluation Among Patients With Drug-Resistant Epilepsy},
  journal = {JAMA Neurology},
  year = {2024},
  doi = {10.1001/jamaneurol.2024.0551}
}
Kostenlos starten →